Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IceCure Medical Ltd.

http://icecure-medical.com/

Latest From IceCure Medical Ltd.

Japan’s Largest Biocluster, Korean Ventures To Collaborate For Cell And Gene Therapies

Japan’s largest biopharma R&D hub has been in active discussions with Korean bioventures for possible collaboration in the cell and gene therapy area. The idea, also backed by the Korean government, started with a paradigm shift during the pandemic.

Japan South Korea

Results Recap: EndoBarrier Improves Obesity And Diabetes Outcomes In UK Study; Procept’s Aquablation Proves Effective Again

Medtech Insight's Results Recap covers major device trial results appearing on MedDeviceTracker. This week's edition covers new clinical data released March 8 to March 22, not including the data presented at the annual conferences of the American Academy of Orthopedic Surgeons or American College of Cardiology, which are presented in separate special editions of Results Recap.

Tracking Trials Clinical Trials

Ablation Therapies Emerging As Gentler Approach To Breast Cancer

Use of ablation technology is emerging as a potentially gentler treatment option for breast cancer, and cryo and thermal ablation in particular are on the verge of regulatory approval that could lead to wider use. A growing number of physicians are already using cryotherapy for breast cancer, but without FDA clearance, reimbursement can be a difficult issue.

Commercial Innovation

Start-Up Quarterly Statistics, Q2 2013

The year might have started off slow for start-up fundraising ($398.7 million in Q1), but during the second quarter of 2013 life science companies rallied and earned a whopping $907.2 million. There were several reverse licensing arrangements as well as alliances involving large molecule-focused start-ups.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Medical Devices
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Other Names / Subsidiaries
    • Arbel Medical
UsernamePublicRestriction

Register